Multifunctional receptor-targeted nanocomplexes for magnetic resonance imaging and transfection of tumours

Biomaterials

Volumn 33, Issue 29, 2012, Pages 7241-7250

  Kenny, Gavin D ^a   Villegas Llerena, Claudio ^a   Tagalakis, Aristides D ^a   Campbell, Frederick ^b   Welser, Katharina ^b   Botta, Mauro ^c   Tabor, Alethea B ^b   Hailes, Helen C ^b   Lythgoe, Mark F ^a   Hart, Stephen L ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

Gene therapy; Liposome; MRI; Nanocomplex; Peptide

Indexed keywords

CONTRAST AGENT; DNA DELIVERY; GENETIC THERAPY; IN-VITRO; IN-VIVO; LOCALISATION; LUCIFERASE EXPRESSION; NANOCOMPLEXES; NEUROBLASTOMAS; NEUROTENSIN; NON-TARGETED; PEPTIDE LIGAND; PLASMID DNA; REAL TIME; REAL TIME MONITORING; SELF-ASSEMBLING; TARGETED DELIVERY; TETANUS TOXIN; TIME COURSE;

CONFOCAL MICROSCOPY; DRUG THERAPY; GADOLINIUM; GENE EXPRESSION; GENE THERAPY; LIPOSOMES; MAGNETIC RESONANCE IMAGING; NUCLEIC ACIDS; PEPTIDES; TUMORS;

MOLECULAR BIOLOGY;

APOLIPOPROTEIN E; GADOLINIUM; LIPOSOME; NANOCOMPLEX; NANOMATERIAL; NEUROTENSIN; PEPTIDE; PLASMID DNA; TETANUS TOXIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONFOCAL MICROSCOPY; FEMALE; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSFECTION; HYDRODYNAMICS; IN VITRO STUDY; IN VIVO STUDY; NEUROBLASTOMA; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; ZETA POTENTIAL;

ANIMALS; CELL LINE, TUMOR; CONTRAST MEDIA; FEMALE; GADOLINIUM; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; KINETICS; LIGANDS; LIPOSOMES; LUCIFERASES; MAGNETIC RESONANCE IMAGING; MICE; MODELS, CHEMICAL; NANOPARTICLES; NANOTECHNOLOGY; NEOPLASM TRANSPLANTATION; NEOPLASMS; NEUROTENSIN; PEPTIDES; TETANUS TOXIN; TRANSFECTION;

EID: 84864311531     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.06.042     Document Type: Article

References (63)

1. Kawabata K., Takakura Y., Hashida M. The fate of plasmid DNA after intravenous injection in mice: involvement of scavenger receptors in its hepatic uptake. Pharmaceut Res 1995, 12:825-830.
2. Fenske D.B., Chonn A., Cullis P.R. Liposomal nanomedicines: an emerging field. Toxicol Pathol 2008, 36:21-29.
3. El Aneed A. An overview of current delivery systems in cancer gene therapy. J Control Release 2004, 94:1-14.
4. Gabizon A.A., Shmeeda H., Zalipsky S. Pros and cons of the liposome platform in cancer drug targeting. J Liposome Res 2006, 16:175-183.
5. Kawakami S., Hashida M. Targeted delivery systems of small interfering RNA by systemic administration. Drug Metab Pharmacokinet 2007, 22:142-151.
6. Kamaly N., Kalber T., Kenny G., Bell J., Jorgensen M., Miller A. A novel bimodal lipidic contrast agent for cellular labelling and tumour MRI. Org Biomol Chem 2010, 8:201-211.
7. Kenny G.D., Kamaly N., Kalber T.L., Brody L.P., Sahuri M., Shamsaei E., et al. Novel multifunctional nanoparticle mediates siRNA tumour delivery, visualisation and therapeutic tumour reduction in vivo. J Control Release 2011, 149:111-116.
8. Mulder W.J., Strijkers G.J., van Tilborg G.A., Griffioen A.W., Nicolay K. Lipid-based nanoparticles for contrast-enhanced MRI and molecular imaging. NMR Biomed 2006, 19:142-164.
9. Erdogan S., Medarova Z.O., Roby A., Moore A., Torchilin V.P. Enhanced tumor MR imaging with gadolinium-loaded polychelating polymer-containing tumor-targeted liposomes. J Magn Reson Imaging 2008, 27:574-580.
10. Song S., Liu D., Peng J., Sun Y., Li Z., Gu J.R., et al. Peptide ligand-mediated liposome distribution and targeting to EGFR expressing tumor in vivo. Int J Pharm 2008.
11. Chen Y., Wu J.J., Huang L. Nanoparticles targeted with NGR motif deliver c-myc siRNA and doxorubicin for anticancer therapy. Mol Ther 2010, 18:828-834.
12. 2 and bcl-2 antisense oligodeoxynucleotide G3139 for enhanced anticancer therapy. Mol Pharm 2009, 6:971-977.
13. Hart S.L., Arancibia-Carcamo C.V., Wolfert M.A., Mailhos C., O'Reilly N.J., Ali R.R., et al. Lipid-mediated enhancement of transfection by a nonviral integrin-targeting vector. Hum Gene Ther 1998, 9:575-585.
14. Siapati K.E., Barker S., Kinnon C., Michalski A., Anderson R., Brickell P., et al. Improved antitumour immunity in murine neuroblastoma using a combination of IL-2 and IL-12. Br J Cancer 2003, 88:1641-1648.
15. Mustapa M.F.M., Grosse S.M., Kudsiova L., Elbs M., Raiber E.-A., Wong J.B., et al. Stabilized integrin-targeting ternary LPD (lipopolyplex) vectors for gene delivery designed to disassemble within the target cell. Bioconjug Chem 2009, 20:518-532.
16. Grosse S.M., Tagalakis A.D., Mustapa M.F.M., Elbs M., Meng Q.-H., Mohammadi A., et al. Tumor-specific gene transfer with receptor-mediated nanocomplexes modified by polyethylene glycol shielding and endosomally cleavable lipid and peptide linkers. FASEB J 2010, 24:2301-2313.
17. Tagalakis A.D., Grosse S.M., Meng Q.-H., Mustapa M.F.M., Kwok A., Salehi S.E., et al. Integrin-targeted nanocomplexes for tumour specific delivery and therapy by systemic administration. Biomaterials 2011, 32:1370-1376.
18. Wong J.B., Grosse S., Tabor A.B., Hart S.L., Hailes H.C. Acid cleavable PEG-lipids for applications in a ternary gene delivery vector. Mol BioSyst 2008, 4:532-541.
19. Mousazadeh M., Palizban A., Salehi R., Salehi M. Gene delivery to brain cells with apoprotein E derived peptide conjugated to polylysine (apoEdp-PLL). J Drug Target 2007, 15:226-230.
20. Tyler B.M., Douglas C.L., Fauq A., Pang Y.-P., Stewart J.A., Cusack B., et al. In vitro binding and CNS effects of novel neurotensin agonists that cross the blood-brain barrier. Neuropharmacology 1999, 38:1027-1034.
21. Martinez-Fong D., Navarro-Quiroga I., Ochoa I., Alvarez-Maya I., Meraz M.A., Luna J., et al. Neurotensin-SPDP-poly-l-lysine conjugate: a nonviral vector for targeted gene delivery to neural cells. Mol Brain Res 1999, 69:249-262.
22. Liu J.K., Teng Q., Garrity-Moses M., Federici T., Tanase D., Imperiale M.J., et al. A novel peptide defined through phage display for therapeutic protein and vector neuronal targeting. Neurobiol Dis 2005, 19:407-418.
23. Park I.-K., Lasiene J., Chou S.-H., Horner P.J., Pun S.H. Neuron-specific delivery of nucleic acids mediated by Tet1-modified poly(ethylenimine). J Gene Med 2007, 9:691-702.
24. III chelates. J Am Chem Soc 2010, 132:7836-7837.
25. Baraldo K., Leforestier N., Bureau M., Mignet N., Scherman D. Sphingosine-based liposome as DNA vector for intramuscular gene delivery. Pharmaceut Res 2002, 19:1144-1149.
26. Cozens A.L., Yezzi M.J., Kunzelmann K., Ohrui T., Chin L., Eng K., et al. CFTR expression and chloride secretion in polarized immortal human bronchial epithelial cells. Am J Resp Cell Mol 1994, 10:38-47.
27. Ma P., Dong X., Swadley C.L., Gupte A., Leggas M., Ledebur H.C., et al. Development of idarubicin and doxorubicin solid lipid nanoparticles to overcome Pgp-mediated multiple drug resistance in leukemia. J Biomed Nano 2009, 5:151-161.
28. Kim J.-Y., Kim J.-K., Park J.-S., Byun Y., Kim C.-K. The use of PEGylated liposomes to prolong circulation lifetimes of tissue plasminogen activator. Biomaterials 2009, 30:5751-5756.
29. Davis M.E., Chen Z., Shin D.M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 2008, 7:771-782.
30. Bainbridge J.W.B., Smith A.J., Barker S.S., Robbie S., Henderson R., Balaggan K., et al. Effect of gene therapy on visual function in leber's congenital amaurosis. New Engl J Med 2008, 358:2231-2239.
31. Cartier N., Hacein-Bey-Abina S., Bartholomae C.C., Veres G., Schmidt M., Kutschera I., et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 2009, 326:818-823.
32. Morgan R.A., Dudley M.E., Wunderlich J.R., Hughes M.S., Yang J.C., Sherry R.M., et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006, 314:126-129.
33. Ott M.G., Schmidt M., Schwarzwaelder K., Stein S., Siler U., Koehl U., et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 2006, 12:401-409.
34. Sumer B., Gao J. Theranostic nanomedicine for cancer. Nanomedicine 2008, 3:137-140.
35. Bartlett D.W., Su H., Hildebrandt I.J., Weber W.A., Davis M.E. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci U S A 2007, 104:15549-15554.
36. Mikhaylova M., Stasinopoulos I., Kato Y., Artemov D., Bhujwalla Z.M. Imaging of cationic multifunctional liposome-mediated delivery of COX-2 siRNA. Cancer Gene Ther 2009, 16:217-226.
37. Grange C., Geninatti-Crich S., Esposito G., Alberti D., Tei L., Bussolati B., et al. Combined delivery and magnetic resonance imaging of neural cell adhesion molecule-targeted doxorubicin-containing liposomes in experimentally induced kaposi's sarcoma. Cancer Res 2010, 70:2180-2190.
38. Li W., Su B., Meng S., Ju L., Yan L., Ding Y., et al. RGD-targeted paramagnetic liposomes for early detection of tumor: in vitro and in vivo studies. Eur J Radiol 2011, 80:598-606.
39. Bertini I., Bianchini F., Calorini L., Colagrande S., Fragai M., Franchi A., et al. Persistent contrast enhancement by sterically stabilized paramagnetic liposomes in murine melanoma. Magn Reson Med 2004, 52:669-672.
40. Nieminen M.T., Rieppo J., Silvennoinen J., Töyräs J., Hakumäki J.M., Hyttinen M.M., et al. Spatial assessment of articular cartilage proteoglycans with Gd-DTPA-enhanced T1 imaging. Magn Reson Med 2002, 48:640-648.
41. III-based contrast agent designed for high magnetic field applications. Contrast Media Mol Imag 2008, 3:78-85.
42. Overoye-Chan K., Koerner S., Looby R.J., Kolodziej A.F., Zech S.G., Deng Q., et al. EP-2104R: a fibrin-specific gadolinium-based MRI contrast agent for detection of thrombus. J Am Chem Soc 2008, 130:6025-6039.
43. Unger E.C., Fritz T.A., Tilcock C., New T.E. Clearance of liposomal gadolinium: in vivo decomplexation. J Magn Reson Imaging 1991, 1:689-693.
44. Mier W., Hoffend J., Kramer S., Schuhmacher J., Hull W.E., Eisenhut M., et al. Conjugation of DOTA using isolated phenolic active esters: the labeling and biodistribution of albumin as blood pool marker. Bioconjug Chem 2005, 16:237-240.
45. Gao H., Shi W., Freund L.B. Mechanics of receptor-mediated endocytosis. Proc Natl Acad Sci U S A 2005, 102:9469-9474.
46. Rubio-Zapata H.A., Rembao-Bojorquez J.D., Arango-Rodriguez M.L., Dupouy S., Forgez P., Martinez-Fong D. NT-polyplex: a new tool for therapeutic gene delivery to neuroblastoma tumors. Cancer Gene Ther 2009, 16:573-584.
47. Gonzalez-Barrios J.A., Lindahl M., Bannon M.J., Anaya-Martinez V., Flores G., Navarro-Quiroga I., et al. Neurotensin polyplex as an efficient carrier for delivering the human GDNF gene into nigral dopamine neurons of hemiparkinsonian rats. Mol Ther 2006, 14:857-865.
48. Frankel A., Tsao M.-S., Viallet J. Receptor subtype expression and responsiveness to bombesin in cultured human bronchial epithelial cells. Cancer Res 1994, 54:1613-1616.
49. Sauer I., Dunay I.R., Weisgraber K., Bienert M., Dathe M. An apolipoprotein E-derived peptide mediates uptake of sterically stabilized liposomes into brain capillary endothelial cells. Biochemistry 2005, 44:2021-2029.
50. Re F., Cambianica I., Zona C., Sesana S., Gregori M., Rigolio R., et al. Functionalization of liposomes with ApoE-derived peptides at different density affects cellular uptake and drug transport across a blood-brain barrier model. Nanomedicine 2011, 7:551-559.
51. Re F., Cambianica I., Sesana S., Salvati E., Cagnotto A., Salmona M., et al. Functionalization with ApoE-derived peptides enhances the interaction with brain capillary endothelial cells of nanoliposomes binding amyloid-beta peptide. J Biotechnol 2011, 156:341-346.
52. Akinc A., Querbes W., De S., Qin J., Frank-Kamenetsky M., Jayaprakash K.N., et al. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther 2010, 18:1357-1364.
53. Yao X., Vitek M.P., Remaley A.T., Levine S.J. Apolipoprotein mimetic peptides: a new approach for the treatment of asthma. Front Pharmacol 2012, 3.
54. Michikawa M., Fan Q.-W., Isobe I., Yanagisawa K. Apolipoprotein E exhibits isoform-specific promotion of lipid efflux from astrocytes and neurons in culture. J Neurochem 2000, 74:1008-1016.
55. Townsend S.A., Evrony G.D., Gu F.X., Schulz M.P., Brown R.H., Langer R. Tetanus toxin C fragment-conjugated nanoparticles for targeted drug delivery to neurons. Biomaterials 2007, 28:5176-5184.
56. Yoshida S., Fukumoto S., Kawaguchi H., Sato S., Ueda R., Furukawa K. Ganglioside GD2 in small cell lung cancer cell lines. Cancer Res 2001, 61:4244-4252.
57. Galli T., Zahraoui A., Vaidyanathan V.V., Raposo G., Tian J.M., Karin M., et al. A novel tetanus neurotoxin-insensitive vesicle-associated membrane protein in SNARE complexes of the apical plasma membrane of epithelial cells. Mol Biol Cell 1998, 9:1437-1448.
58. Bellavance M.-A., Poirier M.-B., Fortin D. Uptake and intracellular release kinetics of liposome formulations in glioma cells. Int J Pharm 2010, 395:251-259.
59. Elouahabi A., Ruysschaert J.-M. Formation and intracellular trafficking of lipoplexes and polyplexes. Mol Ther 2005, 11:336-347.
60. Billiet L., Gomez J.-P., Berchel M., Jaffrès P.-A., Le Gall T., Montier T., et al. Gene transfer by chemical vectors, and endocytosis routes of polyplexes, lipoplexes and lipopolyplexes in a myoblast cell line. Biomaterials 2012, 33:2980-2990.
61. Gopal V., Xavier J., Dar G.H., Jafurulla M., Chattopadhyay A., Rao N.M. Targeted liposomes to deliver DNA to cells expressing 5-HT receptors. Int J Pharm 2011, 419:347-354.
62. Kluza E., Jacobs I., Hectors S.J.C.G., Mayo K.H., Griffioen A.W., Strijkers G.J., et al. Dual-targeting of αvβ3 and galectin-1 improves the specificity of paramagnetic/fluorescent liposomes to tumor endothelium in vivo. J Control Release 2012, 158:207-214.
63. Kamaly N., Kalber T., Ahmad A., Oliver M.H., So P.-W., Herlihy A.H., et al. Bimodal paramagnetic and fluorescent liposomes for cellular and tumor magnetic resonance imaging. Bioconjug Chem 2008, 19:118-129.